Bob Azelby CEO of Alder Biopharmaceuticals and Erin Lavelle COO

Discussion in 'Amgen' started by anonymous, Jun 8, 2018 at 3:02 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    They are coming to fuck Amgen in migraine after Lilly and Teva do their raping.

    Enjoy the short honeymoon!

    After a couple years the Allergan CGRP oral will bring down all the injectable biologics.

    Alder BioPharmaceuticals® Names Robert W. Azelby President and Chief Executive Officer
    Former executive at Juno Therapeutics and Amgen, Azelby brings deep operational and commercialization expertise

    BOTHELL, Wash., June 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today named biotech industry veteran Robert W. Azelby president and chief executive officer of Alder, effective June 13, 2018. He also will serve on the company’s board of directors.

    Mr. Azelby joins Alder from Juno Therapeutics, Inc., where he served as executive vice president and chief commercial officer. He was responsible for the development and implementation of Juno’s CAR-T commercial strategy. Mr. Azelby was a member of Juno’s executive management team and helped guide the organization through rapid growth and ultimately, to a $9 billion acquisition by Celgene Corporation. He succeeds Paul B. Cleveland, who has been acting as Alder’s interim president and chief executive officer. Mr. Cleveland will continue to serve on the company’s board of directors.

    “We are thrilled to have Bob join Alder at this key stage in the company’s history. He is a seasoned leader who brings significant operational experience and a strong track record in both large and small biopharmaceutical environments, and his skills will be of great value as we progress our CGRP inhibitor, eptinezumab, towards approval and commercialization for migraine prevention,” said Mr. Cleveland. “We look forward to Bob’s leadership as we continue to deliver on our commitment to transform the treatment paradigm for migraine prevention to benefit the millions of underserved patients living with migraine and create value for our shareholders.”

    “Eptinezumab has the potential to make a significant difference in the lives of people dealing with the debilitating effects of migraine,” Mr. Azelby said. “I am excited to join Alder at this pivotal time for both the company and the migraine community.”



     

  2. anonymous

    anonymous Guest

    Not likely. Orals will only penetrate the primary care market and only as an acute treatment in triptan intolerant, not preventative. The mAbs and Botox will still own the prevention market in headache centers and specialized neurons.
     
  3. anonymous

    anonymous Guest

    Depends on the trials and the chronic tolerability profile.

    It will be a battle of confidence of oral vs the side effect profile - as long as the GI tract issues like nasea and diarrhea are minimal - they will be preferred.
     
  4. anonymous

    anonymous Guest

    Lavelle and Azelby - boom chicka bow wow! Cue the sleazy porn music!
     
  5. anonymous

    anonymous Guest

    You can't sell a drug to lower cholesterol. How you gonna sell a $7000 injection for an excedrin headache?